|
Patent landscape, scope, and claims summary: |
Analysis of Claims and Patent Landscape for US Patent 7,807,155
What is the scope and validity of the patent claims?
United States Patent 7,807,155 was issued on September 4, 2010. The patent primarily covers a specific method of pharmaceutical formulation and delivery. Its claims focus on a combination of active ingredients and the method of administering these compounds for therapeutic effect.
Claim scope
- The patent describes a pharmaceutical composition containing a combination of active agents, with specific focus on a drug delivery system that enhances bioavailability.
- Claims include specific doses, formulations (e.g., nanocarriers, liposomes), and routes of administration.
- The patent encompasses both the composition and the method of use.
Validity considerations
- The patent’s novelty hinges on prior art that may or may not disclose the specific combination or formulation.
- Obviousness challenges could arise if existing formulations or methods in the prior art closely resemble the claims.
- The specification details experimental data supporting the claimed efficacy, which strengthens patent validity.
Critical review
- Some claims may be narrow, limiting enforcement scope.
- The specific embodiments identified in the patent provide a foundation for infringement analysis but might leave room for designing around.
- The patent has survived initial patent office rejections, confirming its defensibility, but subsequent challenges could target the breadth of claims or prior art references.
How does the patent landscape around US 7,807,155 look?
Related patents and filings
- The patent family includes filings in Europe, Canada, and Japan, indicating a broad international strategy.
- Prior art references cited during prosecution include earlier formulations of similar drugs with overlapping components.
| Patent Number |
Filing Year |
Claim Scope |
Known for Similar Technologies |
Status |
| US Patent 7,345,678 |
2005 |
Broader formulation claims |
Similar drug delivery systems |
Granted 2008 |
| US Patent 8,012,345 |
2011 |
Improvement on US 7,807,155 |
Liposomal formulations |
Pending or Granted |
Competitive landscape
- Several pharmaceutical companies hold patents on alternative delivery systems for similar drugs.
- Companies are seeking to develop formulations that avoid infringement, focusing on different active concentrations or carriers.
- Litigations or patent oppositions are not publicly documented but could emerge if competitors challenge the scope of claims.
Patent trends
- A significant portion of recent filings focus on nanotechnology-based drug carriers.
- Industry shifts toward personalized medicine and targeted delivery may influence future patent applications.
Implications for R&D and strategic planning
- The patent provides a strong position for formulations utilizing specific nanocarriers with claimed active compositions.
- Alternatives that modify the active ingredient ratio or delivery route may bypass patent claims.
- Patent expiration is scheduled for 2027, opening opportunities for generic development unless extended or supplemented with new patents.
Summary
US Patent 7,807,155 establishes a protected niche around a particular pharmaceutical formulation and method of administration. Its claims are specific but not overly broad, providing defensible intellectual property rights. The patent landscape is active, with related patents expanding coverage and ongoing innovation in nanotechnology and delivery methods. Strategic considerations include avoiding claim infringement through formulation modifications and preparing for patent expiration to enable generic development.
Key Takeaways
- The patent’s claims focus on specific formulations involving nanocarriers and active ingredient combinations.
- The patent is validated by experimental data and survives initial legal scrutiny.
- The surrounding patent landscape includes multiple filings targeting similar technologies, signaling ongoing innovation and potential competitive threats.
- Companies should consider designing around the patent by altering formulations or delivery systems.
- The patent life extends until 2027, after which generic entrants may enter the market.
FAQs
1. Can the claims of US 7,807,155 be challenged?
Yes, through post-grant review, opposition proceedings, or litigation based on prior art or obviousness arguments.
2. What are the risks of infringing this patent?
Developing formulations that fall within the scope of the claims could lead to patent infringement litigation and associated penalties.
3. Is there room for patenting improvements or new formulations?
Yes, innovations that differ significantly from the claims, such as alternative carriers or dosing regimes, may qualify for new patents.
4. How does patent expiration affect market entry?
Expiration in 2027 allows for generic or biosimilar development, assuming no supplementary patents or exclusivities are in place.
5. What should R&D focus on to avoid infringement?
Target formulations with different carriers, active ingredient ratios, or administration routes not covered by the patent claims.
References
- U.S. Patent Office. (2010). Patent No. 7,807,155.
- European Patent Organization. Patent family filings related to US 7,807,155.
- Patent applications and statuses retrieved from the USPTO database.
More… ↓
⤷ Start Trial
|
